
Inhaltsverzeichnis
Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt). - The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler
and Yosef Yarden). - Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch
and Guenther G. Steger). - Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello). - Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu). - Pertuzumab a HER-2 dimerisation inhibitor for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni). - Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
From the reviews:
This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing. (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)
Es wurden noch keine Bewertungen abgegeben. Schreiben Sie die erste Bewertung zu "Drugs for HER-2-positive Breast Cancer" und helfen Sie damit anderen bei der Kaufentscheidung.